CD274 and non-small cell lung carcinoma: To investigate this, the economic evaluations included in this review [9,10,13,21,24,29,30,31,32,34,37,42] confirmed that NSCLC patients with high tumour PD-L1 levels with a proportional score ≥ 50% for first-line therapy with pembrolizumab, exhibited superior response rates to immunotherapy and experienced prolonged survival compared to those who underwent conventional chemotherapy.